y available cardiac safety screening expertise and technologies.
With this new service, we will design and execute stronger preclinical
studies to help eliminate the risk of cardiac safety issues in drugs before
they hit the pipeline" said Dr. Judith Gwathmey, President and CSO of
Gwathmey Preclinical Testing Services, Inc.
Features of Gwathmey Preclinical's Cardionomics(TM) Services include:
-- Cardiac catheterization
-- Pressure-volume determinations
-- Isolated perfused hearts
-- Isolated muscle studies (animal and human)
-- Human heart failure tissue cDNA array for human pharmacogenomics and
These kinds of pre-clinical services on animal models are typically
only available in major university settings, which can make easy and
immediate access to them difficult.
"Dr. Judith Gwathmey has a record of performing important work in heart
failure over several decades. Cardionomics(TM) is an extension of her
interest and expertise in this arena. Support for development of highly
innovative management strategies will facilitate drug discovery, a needed
boost for the field of heart failure," said Gary S. Francis, M.D., Section
Head, Clinical Cardiology at the Cleveland Clinic.
Dr. Gwathmey, who conceived this new service concept, is a
world-renowned cardiac scientist. She has one of the most cited papers in
heart failure research on calcium handling in human myocardium. It has
remained in the top fifty most cited papers for over 25 years. Dr. Gwathmey
has authored over 160 manuscripts on cardiovascular disease including
arrhythmias, cardiac myocyte function, ischemia and global heart function
in normal and disease states. She is the author of the highly regarded text
book: "Heart Failure: Basic Science and Clinical Medicine," cited by the
New England Journal of Medicine.
In support of the new services, Gwat
Page: 1 2 3 4 Related biology technology :1
|SOURCE Gwathmey Preclinical Testing Services, Inc.|
Copyright©2008 PR Newswire.
All rights reserved
. Increased Light Leads to Early Detection: Caliper Life Sciences Introduces Bioware(R) Ultra Cancer Cell Lines2
. APIC Statement on Need for Increased Prevention Measures for Healthcare-Associated Infections (HAIs)3
. Kiwa Bio-Tech Animal Feed Volume Increased 25% in Fourth Quarter of 20074
. Novo Nordisk Increased Operating Profit by 11% in the First Nine Months of 2007 Based on a 9% Sales Increase and an Improved Gross Margin5
. VaxGen Sells Anthrax Vaccine Program and Related Assets and Technology to Emergent BioSolutions, Inc.6
. Vasogen Receives NASDAQ Notification Related to Minimum Bid Price7
. Intellect Neurosciences, Inc. Receives Notice of Allowance and Completes Grant Requirements for Pivotal European Patent Related to Passive Immunization of Alzheimers Disease8
. District Judge Dismisses Shareholder Suit Related to Boston Scientific9
. Graceway Pharmaceuticals, LLC(TM) Announces Completed Acquisition of All Assets Related to Estrasorb(R) Product Line in North America From Allergan, Inc. (NYSE: AGN) and Novavax, Inc. (Nasdaq: NVAX)10
. Alexion Acquires All Rights to OMRF Patents Related to Soliris(R)11
. TAP Pharmaceutical Products Inc. Files New Drug Application for TAK-390MR in Patients with Acid-Related Disorders